Biotech Prediction Bets on Trials Prompt Ethical Backlash

Kalshi’s plan to let users bet on the outcomes of clinical trials has drawn sharp ethical objections from researchers and patients who warn such markets could undermine trial integrity and patient welfare, even as Kalshi argues bets would reflect updated evidence and cut through hype. The controversy highlights broader concerns about gamifying lifesaving research and treating trials as speculative bets, rather than purely scientific endeavors.